Covidien gets Canadian OK for generic sestamibi

Healthcare technology firm Covidien has received approval from Health Canada for its generic technetium-99m sestamibi kit.

The myocardial perfusion imaging radiopharmaceutical can be substituted for the Cardiolite agent from Lantheus Medical Imaging of North Billerica, MA, according to Covidien of Dublin, Ireland. Covidien said it expects the kit will be available to Canadian customers this summer.

Related Reading

Covidien closes VNUS purchase, June 18, 2009

Covidien to acquire VNUS for $440M, May 8, 2009

Covidien adds to Q2 sales, May 1, 2009

Covidien, B&W to tackle medical isotope dilemma, January 28, 2009

Covidien to move HQ to Ireland, January 7, 2009

Copyright © 2009

Page 1 of 436
Next Page